Table 1.
Average Cost per RSV Hospitalization for All Payers by Gestational Age and Special Populations Group (2020 US$)
| Study Label | Sample Size, n Original (Adjusted) | Mean (95% CI) |
|---|---|---|
| Full term | ||
| Goldstein, 2018a (I) [24] | 3657 (2438) | 12 418 (11 199–13 637) |
| Krilov, 2020a (I) [38] | 1654 (1115) | 18 473 (16 802–20 143) |
| Ledbetter, 2020a (I) [39] | 19 473 (10 277) | 7242 (6331–8153) |
| McLaurin, 2016a (I) [40] | 38 372 (31 337) | 10 722 (10 251–11 196) |
| Wyffels, 2017 (C) [46] | 722 (523) | 8794 (8200–9388) |
| Full term (≥37 wGA) averageb (I) | 63 156 (45 167) | 10 214 (9818–10 610) |
| Full term (≥37 wGA) averageb (C) | 63 878 (45 690) | 10 198 (9807–10 590) |
| Late preterm | ||
| Anderson, 2017 (I) [25] | 34 (34) | 22 623 (13 810–31 436) |
| Ledbetter, 2020a (I) [39] | 2736 (1824) | 10 799 (9902–11 695) |
| McLaurin, 2016a (I) [40] | 3813 (3050) | 15 117 (13 895–16 339) |
| Late preterm (35–36 wGA) averageb (I) | 6583 (4908) | 13 564 (12 730–14 398) |
| Late preterm (35–36 wGA) averageb (C) | 6583 (4908) | 13 564 (12 730–14 398) |
| Early preterm | ||
| Anderson, 2017a (I) [25] | 149 (149) | 21 813 (17 764–25 863) |
| Goldstein, 2018a (I) [24] | 654 (436) | 26 178 (19 455–32 901) |
| Krilov, 2020a (I) [38] | 186 (125) | 44 088 (21 257–66 919) |
| Ledbetter, 2020a (I) [39] | 2600 (1372) | 19 746 (17 480–22 011) |
| McLaurin, 2016a (I) [40] | 3305 (2699) | 21 484 (19 451–23 517) |
| Wozniak, 2016a (C) [45] | 177 (177) | 11 680 (8928–14 432) |
| Wyffels, 2017 (C) [46] | 282 (204) | 12 019 (10 214–13 825) |
| Early preterm (29–34 wGA) averageb (I) | 6894 (4782) | 22 016 (20 435–23 596) |
| Early preterm (29–34 wGA) averageb (C) | 7353 (5163) | 21 266 (19 796–22 736) |
| Extremely preterm | ||
| Ledbetter, 2020a (I) [39] | 710 (355) | 76 614 (55 933–97 295) |
| McLaurin, 2016a (I) [40] | 787 (630) | 46 575 (32 175–60 975) |
| Extremely preterm (≤28 wGA) averageb (I) | 1497 (985) | 57 406 (45 529–69 282) |
| Extremely preterm (≤28 wGA) averageb (C) | 1497 (985) | 57 406 (45 529–69 282) |
| Overall, and other | ||
| All payer overall averagec (I) | 78 130 (55 842) | 11 973 (11 577–12 369) |
| All payer overall averageb (C) | 79 311 (56 746) | 12 315 (11 905–12 725) |
| Doucette, 2016a (I) [23] | 729 894 (729 894) | 4248 (4230–4265) |
| Gupta, 2016 (C) [35] | 146 357 (146 357) | 16 252 (15 921–16 583) |
| Rivera-Sepulveda, 2017a (C) [41] | 5050 (5050) | 5055 (4947–5163) |
| Shah, 2017 (C) [42] | 19 083 (19 083) | 7204 (6699–7708) |
| Unspecified wGA averageb (I) | 729 894 (729 894) | 4248 (4230–4265) |
| Unspecified wGA averageb (C) | 900 384 (900 384) | 6266 (6209–6324) |
| Chu, 2017a (C) [32] | 4049 (2025) | 66 593 (45 220–87 967) |
| Doucette, 2016a (I) [23] | 45 203 (22 602) | 11 320 (10 476–12 164) |
| Ledbetter, 2020a (I) [39] | 4077 (4077) | 13 047 (10 898–15 196) |
| Walpert, 2018a (C) [44] | 625 (625) | 18 353 (14 824–21 881) |
| Special populations averageb (I) | 49 280 (26 679) | 11 584 (10 797–12 370) |
| Special populations averageb (C) | 53 954 (29 328) | 15 525 (13 876–17 174) |
Abbreviations: C, children aged 0–59 months; CI, confidence interval; I, infants aged 0–12 months; RSV, respiratory syncytial virus; wGA, weeks’ gestational age; 2020 US$, United States dollars at 2020 prices.
Within-study weighted average.
Across-study weighted average from all applicable gestational age group studies, adjusted for overlapping samples.
Across-study weighted average adjusted using national data, excludes unspecified wGA and special populations, adjusted for overlapping samples; weights assume that wGA was missing at random for the 5/704 (0.7%) infants and the 9/903 (1.0%) children in the national sample data with unknown wGA.